Vivos Inc. (OTCMKTS:RDGLD) is a Richland, Washington-based late stage development company engaged primarily in the development of brachytherapy devices for therapeutic applications. RDGL's focus is on transitioning to full operations upon receipt, if any, of FDA clearance for its patented brachytherapy cancer products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.
Since late 2013, RDGL has focused its resources on developing a proposed line of brachytherapy products and on endeavoring to secure FDA clearance with respect to the initial proposed brachytherapy product. RDGL's proposed brachytherapy products incorporate patented technology developed for Battelle Memorial Institute (“Battelle”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted RDGL an exclusive license to patents covering these developments for manufacturing, processing and applications for medical isotopes (the “Battelle License”).
A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead RDGL’s development efforts. RDGL has been recognized as a leader in the development of new isotope technologies by local, state and federal agencies.
The Company’s overall objective is to empower physicians, medical researchers, and ultimately, patients, by providing them with essential radionuclides that, until now, have not been practical or economical to produce, in an effort to detect, manage, and cure human disease, and improve the lives of patients. The Company’s shorter-term objective is to obtain regulatory approval for its brachytherapy products and to then commercialize those products.
|Jan 13, 2020||Vivos Inc. Provides 2019 Recap and Outlines 2020 Objectives|
|Dec 03, 2019||Vivos Inc. Treats Additional Patients at its Pilot Clinic|
|Oct 22, 2019||Vivos Inc. Reports on IsoPet® Therapy at the Veterinary Cancer Society Annual Meeting|
|Sep 18, 2019||Vivos Inc. Announces Listing to the OTCQB|
|Jul 29, 2019||Vivos Inc. Stock Symbol Reverts to RDGL University of Missouri Report Near Completion|
|Day Range||0.0330 - 0.0349|
|52 Week Range||0.0038 - 0.0700|
|Bid/Ask||0.0330 / 0.0346|
|Bid/Ask Size||76,027 X 43,257|
|Market Cap||6.38 million|
|Shares Outstanding||184.35 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|
|Filing Date||Form Type||Description|
|Nov 14, 2019||10-Q/A||Quarterly report (Amendment)||html pdf|
|Nov 12, 2019||10-Q||Quarterly report||html pdf xbrl|
|Aug 13, 2019||10-Q||Quarterly report||html pdf xbrl|
|Jun 24, 2019||10-Q/A||Quarterly report (Amendment)||html pdf xbrl|
|May 13, 2019||10-Q||Quarterly report||html pdf xbrl|